Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

A V Balar, D E Castellano, P Grivas, D J Vaughn, T Powles, J Vuky,Y Fradet,J-L Lee,L Fong, N J Vogelzang, M A Climent,A Necchi, D P Petrylak,E R Plimack, J Z Xu, K Imai, B H Moreno,J Bellmunt,R de Wit,P H O'Donnell

Annals of Oncology（2023）

引用 19|浏览28

暂无评分

摘要

•This analysis investigated the durability of response to pembrolizumab (pembro) in the KEYNOTE-045 and KEYNOTE-052 trials.•Pembro had durable efficacy and manageable safety in patients with metastatic UC after 5 years.•Patients with stable disease or response to pembro who stopped therapy benefited from a second course if disease progressed.•These results support use of pembro in second-line (platinum-refractory) and first-line (cisplatin-ineligible) metastatic UC.

查看译文

关键词

urothelial carcinoma,pembrolizumab,cisplatin-ineligible,cisplatin resistant/refractory

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要